Take a look at some of the biggest movers in the premarket: BioNTech (BNTX) – The…
Month: November 2022
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
AGOURA HILLS, Calif.–(BUSINESS WIRE)–A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development…
Samenvatting: REgiMMUNE presenteert resultaten van de fase 2b-studie van RGI-2001 op de jaarlijkse bijeenkomst van de American Society of Hematology in 2022
TAIPEI, Taiwan–(BUSINESS WIRE)–REgiMMUNE Limited, een biofarmaceutisch bedrijf in de klinische fase dat zich richt op het…
Resumen: REGiMMUNE presentar? los resultados del estudio de fase 2b de RGI-2001 en la reuni?n anual de 2022 de la Sociedad Americana de Hematolog?a
TAIP?I, Taiw?n–(BUSINESS WIRE)–REGiMMUNE Limited, una empresa biofarmac?utica en fase cl?nica centrada en la creaci?n de inmunoterapias…
Riassunto: REGiMMUNE presenter? i risultati dello studio di Fase 2b di RGI-2001 in occasione dell'American Society of Hematology Annual Meeting 2022
TAIPEI, Taiwan–(BUSINESS WIRE)–REGiMMUNE Limited, azienda biofarmaceutica in fase clinica focalizzata sulla creazione di immunoterapie innovative per…
REGiMMUNE pr?sentiert Ergebnisse der Phase-2b-Studie von RGI-2001 auf der Jahrestagung 2022 der American Society of Hematology
TAIPEH, Taiwan–(BUSINESS WIRE)–REGiMMUNE Limited, ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung innovativer…
OREM, Utah–(BUSINESS WIRE)–Digital health software platform, Videra Health, announced today a partnership with California-based behavioral health…